# US 2021/0333283 A1 · Cancer-related activity sensors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0333283 A1
- Document ID: US20210333283A1
- Status: Published application
- Kind: A1
- Application number: 17/238,585
- Filed: 2021-04-23
- Published: 2021-10-28
- Earliest claimed: 2020-04-24
- Assignees: Glympse Bio, Inc.
- Applicants: Glympse Bio, Inc.
- Inventors: James Bowen; Faycal Touti
- Web page: https://patentgrep.com/patent/US20210333283A1

## CPC

- G01N 33/54353: {with ligand attached to the carrier via a chemical coupling agent (coatings G01N33/54393)}
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- C12Q 1/37: involving peptidase or proteinase
- G01N 33/575: for cancer
- G01N 2333/95: Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

An activity sensor sensitive to enzymes indicative of the presence of cancer is used to provide non-invasive reporting of tumor development and response to anticancer therapies useful in determining suitability and effectiveness of various treatments including immuno-oncological therapies. Localized reporters are used in patient stratification in clinical trials, monitoring of drug response or disease progression, and differentiating between anti-tumor immune response, tumor progression, and off-target immune response. Activity sensors may include tuning domains to modulate tissue localization and residency. Periodic measurements of activity sensor reporters may be analyzed to determine a velocity value indicative of disease prognosis.

## Claims

### Claim 1

A method of detecting or monitoring cancer progression comprising:
administering to a patient suspected of having cancer an activity sensor comprising a carrier linked to a reporter molecule by a cleavable linker containing a cleavage site of a cancer-related enzyme;
collecting a sample from the patient;
analyzing the sample to detect the presence or lack of the reporter wherein the presence or lack of the reporter is indicative of cancer status for the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer-related enzyme is an immunological enzyme and presence of the reporter is indicative of an anti-tumor immune response.

### Claim 3 (depends on 2)

The method of claim 2, wherein the presence of the reporter is indicative of therapeutic effect of an immuno-oncology treatment.

### Claim 4 (depends on 3)

The method of claim 3, wherein said therapeutic effect is a measure of resistance to a pharmaceutical treatment.

### Claim 5 (depends on 1)

The method of claim 1, wherein said reporter is a near-IR dye, a nucleic acid barcode, or a protein biomarker.

### Claim 6 (depends on 1)

The method of claim 1, wherein said carrier is a synthetic carrier.

### Claim 7 (depends on 1)

The method of claim 1, wherein said carrier is a naturally-occurring carrier.

### Claim 8 (depends on 1)

The method of claim 1, wherein said administering step is selected from the group consisting of intravenous, oral, transdermal, inhalation, and intracerebral.

### Claim 9 (depends on 3)

The method of claim 3, wherein the activity sensor further comprises a tuning domain operable to localize the activity sensor in a target tumor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer-related enzyme is an enzyme differentially expressed during tumor growth and the presence of the reporter is indicative of tumor growth.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer-related enzyme is an enzyme differentially expressed during cell death, and wherein the presence of the reporter is indicative of a therapeutic response to the anti-cancer therapy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the patient has not undergone immuno-oncology treatment and the presence of the reporter is indicative of a predicted therapeutic response to a checkpoint inhibitor therapy.

### Claim 13 (depends on 1)

The method of claim 1, further comprising stratifying the patient in a clinical trial based on the detection of the reporter in the sample.

### Claim 14 (depends on 1)

The method of claim 1, wherein the analyzing step further comprises quantifying a level of the reporter in the sample, the method further comprising:
periodically repeating the administering, collecting, and analyzing steps to prepare a chronological series of reporter levels, and
determining a velocity of the characteristic indicative of cancer progression in the patient.

### Claim 15 (depends on 1)

The method of claim 1, wherein the immunological enzyme is selected from the group consisting of a caspase and a serine protease.

### Claim 16

An activity sensor for monitoring cancer progression, the activity sensor comprising:
a carrier comprising one or more molecular subunits;
a plurality of detectable reporters, each linked to the carrier by a cleavable linker containing the cleavage site of a cancer-related enzyme; and
a tuning domain operable to localize the activity sensor in a target tumor, wherein the activity sensor reports activity of one or more cancer-related enzymes by releasing the reporters upon cleavage by the one or more cancer-related enzymes.

### Claim 17 (depends on 16)

The activity sensor of claim 16, wherein the cancer-related enzyme is an immunological enzyme.

### Claim 18 (depends on 17)

The activity sensor of claim 17, wherein the immunological enzyme is selected from the group consisting of a caspase and a serine protease.

### Claim 19 (depends on 16)

The activity sensor of claim 16, wherein the tuning domain comprises ligands for receptors of the target tumor.

### Claim 20 (depends on 16)

The activity sensor of claim 16, wherein carrier comprises a polyethylene glycol (PEG) scaffold of covalently linked PEG subunits.
